Abstract
Pneumococcal conjugate vaccine (PCV) is included in the World Health Organization's routine immunization schedule and is recommended by WHO for vaccination in high-risk children up to 60 months. However, many countries do not recommend vaccination in older age groups, nor have donors committed to supporting extended age group vaccination. To better inform decision-making, this systematic review examines the direct impact of extended age group vaccination in children over 12 months in low and middle income countries. An a priori protocol was used. Using pre-specified terms, a search was conducted using PubMed, LILACS, Cochrane Infectious Diseases Group Specialized Register, Cochrane Central Register of Controlled Trials, CAB Abstracts, clinicaltrials.gov and the International Symposium on Pneumococci and Pneumococcal Diseases abstracts. The primary outcome was disease incidence, with antibody titers and nasopharyngeal carriage included as secondary outcomes. Eighteen studies reported on disease incidence, immune response, and nasopharyngeal carriage. PCV administered after 12 months of age led to significant declines in invasive pneumococcal disease. Immune response to vaccine type serotypes was significantly higher for those va...Continue Reading
References
Sep 11, 2007·Internal Medicine·Hiroshi WatanabeOsamu Kunii
Apr 26, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
May 6, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
Aug 30, 2008·Annals of Tropical Paediatrics·R IrisoA Kisayke
Nov 6, 2009·Clinical and Vaccine Immunology : CVI·Jan T PoolmanIsabelle Henckaerts
Jan 26, 2011·MBio·Lone SimonsenKeith P Klugman
Mar 17, 2011·The Pediatric Infectious Disease Journal·María Catalina PírezAlicia Montano
Mar 29, 2011·Human Vaccines·Rosanna E LagosLode Schuerman
Jul 7, 2011·Vaccine·Chareeya ThaneeThanyawee Puthanakit
Oct 27, 2011·PLoS Medicine·Anna RocaRichard A Adegbola
Apr 13, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel M Musher
May 25, 2012·Vaccine·UNKNOWN WHO Publication
Jun 16, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A RocaR A Adegbola
Aug 24, 2012·PloS One·Martin O C OtaRichard A Adegbola
Sep 5, 2012·Tropical Medicine & International Health : TM & IH·Xavier Bosch-CapblanchA Burton
Nov 21, 2012·BMJ Open·Linda HornshøjAne Bærent Fisker
Jan 8, 2013·Human Vaccines & Immunotherapeutics·Alassane DickoLode Schuerman
Apr 16, 2013·Lancet·Christa L Fischer WalkerRobert E Black
Oct 3, 2013·PloS One·Anna RocaMartin Antonio
Dec 21, 2013·Human Vaccines & Immunotherapeutics·Olumuyiwa O OdusanyaLode Schuerman
Jan 28, 2014·PloS One·Laura L HammittJ Anthony G Scott
Jan 28, 2014·PloS One·Olivier Le Polain de WarouxW John Edmunds
Apr 15, 2014·The Lancet. Respiratory Medicine·Carla Magda Allan S DominguesUNKNOWN Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group
Jun 4, 2014·PloS One·Ana Lucia AndradeRuth Minamisava
Jul 11, 2014·Clinical and Vaccine Immunology : CVI·Sanjay LalwaniDorota Borys
Jul 30, 2014·Vaccine·Carlos P DotresUNKNOWN Havana-Pneumococci Group
Aug 12, 2014·The Lancet Global Health·Keith P Klugman
Aug 12, 2014·The Lancet Global Health·Laura L HammittJ Anthony G Scott
Aug 26, 2014·BMC Public Health·Abdi Nur MohamudHardeep Rai Sharma
May 29, 2015·Human Vaccines & Immunotherapeutics·Alassane DickoLode Schuerman
Citations
Mar 1, 2017·Tropical Medicine & International Health : TM & IH·James M Stuart
Dec 13, 2016·PloS One·Lucia Helena de OliveiraCristiana M Toscano
Feb 14, 2020·PloS One·Abdullah H BaquiUNKNOWN Projahnmo Study Group in Bangladesh
Jul 14, 2017·Pneumonia·Serena TricaricoStuart C Clarke
Apr 16, 2021·Expert Review of Vaccines·Lassané KaboréAlain Gervaix
Jun 11, 2021·PloS One·Elodie BesnierClare Bambra
Sep 2, 2021·Vaccine·Abdullah H BaquiUNKNOWN Projahnmo Study Group in Bangladesh